\

About Beaubrain

OUR STORY

BeauBrain Healthcare envisions a world where all people can be free from the obscure fear of dementia. We are currently working on developing an artificial intelligence (AI) program to predict ATN biomarkers for early diagnosis of dementia, as well as DTx for preventing and treating dementia. Additionally, we are making efforts to create a platform for brain health management. Our ultimate goal is to become a leading company in the realization of precision medicine for dementia.

Characteristics of Alzheimer’s Dementia

Alzheimer’s dementia, which accounts for 70% of dementia cases, is a disease that can be prevented or delayed by early diagnosis as the accumulation of Amyloid Beta, Tau, Neurodegeneration (ATN) lesions in the brain begins approximately 10 years before the onset. Under the current clinical practice guideline, if a patient visits a hospital due to cognitive decline and is diagnosed with dementia, the patient can be considered to have already developed brain atrophy.

About Beaubrain

OUR FOUNDERS

BeauBrain Healthcare was founded by world-renowned scientists and neurologists Dr. Na (Duk Ryul) and Dr. Seo (Sang Won) from Samsung Medical Center, in collaboration with Mint Venture Partners, a biotech and healthcare specialized global company builder.

Scientific Co-Founders

Sang Won Seo, MD, Ph.D

Sang Won Seo, MD, Ph.D

Chief Executive Officer

Scientific Co-Founders

Duk Ryul Na, MD, Ph.D

Duk Ryul Na, MD, Ph.D

Chief Medical Officer

Company Builder

MInt Venture Partners

MInt Venture Partners

Company Builder

Jae-Hoon Song, MD, Ph.D

Jae-Hoon Song, MD, Ph.D

Chairman of the Board

About Beaubrain

OUR STRENGTH

For any disease, prevention is more important than treatment. Early diagnose of dementia is the starting point for the best treatment and successful prevention. BeauBrain solutions encompassing all types of dementia are built on differentiated technical skills and abundant high-quality data. The global networks and verified clinical data possessed by BeauBrain Healthcare enable us to advance into the global market early, beyond the local market.

Differentiated technical skills

  • Predicting beta-amyloid positivity using MRI/CT scans only
  • Reading highly versatile and compatible AI images
  • Ensuring the reliability and accuracy of data (AUC of up to 0.95)
  • Enabling continuous technology and product development in collaboration with Samsung Medical Center

Rapid market penetration

  • Possessing multiple product pipelines already proven and utilized in clinical settings
  • Having an efficient investment attraction strategy and efficient organizational structure
  • Providing not only diagnostic aids but also novel values, such as predicting Amyloid, Tau, Neurodegeneration (ATN) or enabling preemptive reimbursement listing for new health technology based on prognosis prediction

High-quality data and evidence

  • Amyloid PET and CT data obtained from at least 7,000 individuals
  • MRI and CT data obtained from at least 30,000 individuals
  • Genomic data obtained from at least 30,000 individuals
  • Cognitive function findings and patient data obtained in clinical settings

Diverse Expertise & Global Network

  • Prominent neurologists specializing in Alzheimer’s disease
  • Healthcare, business strategy, AI/IT specialists on board
  • Mint Venture Partners’ global medical networks

About Beaubrain

OUR PARTNERS